Intellia Reports ATTR Trial Enrollment Completion and Lonvo-z PDUFA Date

What happened

Intellia Therapeutics' Q3 2026 update confirms that lonvo-z remains on track for a March 10, 2027 PDUFA date, with commercial readiness efforts ahead of schedule. The company also announced completion of enrollment in its Phase 3 MAGNITUDE-2 trial for ATTRv-PN and advanced enrollment in the MAGNITUDE trial for ATTR-CM, indicating the FDA clinical hold on nex-z has been lifted and the program is progressing. Intellia plans to present new lonvo-z patient perspectives and Phase 1/2 durability data at the ACAAI meeting, which could provide additional evidence of long-term efficacy and safety. Financially, the company now expects existing cash, supplemented by a recent term loan, to fund operations into 2028, extending its runway beyond the anticipated lonvo-z launch and reducing near-term dilution risk. These developments address two key concerns from the prior HOLD thesis—the clinical hold and funding runway—and shift the risk/reward balance more favorably, though execution and competitive dynamics remain critical.

Implication

For investors, the lifting of the clinical hold on nex-z removes a major overhang, as the ATTR program is now advancing toward potential registration, with enrollment completed in one trial and ongoing in another. The specific PDUFA date for lonvo-z of March 10, 2027 provides a concrete regulatory milestone, which was previously only a general plan, and suggests the BLA submission was well-received by the FDA. The extended cash runway into 2028, bolstered by the term loan, alleviates concerns about a near-term dilutive financing, giving the company flexibility to fund launch and ongoing trials. However, the HAE market remains highly competitive with recent approvals of Andembry and Dawnzera, so lonvo-z will need to demonstrate superior efficacy, safety, or convenience to secure payer access and market share. Additionally, while enrollment completion in MAGNITUDE-2 is positive, the actual efficacy and safety data from these Phase 3 trials are still pending and will ultimately determine the value of the ATTR franchise.

Thesis delta

The prior thesis was a HOLD due to the FDA clinical hold on nex-z and long-dated catalysts, with a key watch item being the resolution of the hold. The Q3 2026 update indicates the hold has been resolved, as enrollment in MAGNITUDE-2 is complete and MAGNITUDE is progressing, and lonvo-z now has a PDUFA date. This shifts the thesis to a more constructive stance, though the ultimate buy/sell decision hinges on upcoming Phase 3 data for both programs.